228 / 1068
Other trials randomising after CRT
TRIAL
Patient
number
Primary
endpoint
OS
DFS
HR for DFS
QUASAR
(92% stage
II)
3239 overall
968 rectal
203 preop RT
all-cause
mortality.
80% versus
83.4%
Not stated 0.78 CI [0.44-
1.22]
(
p=0·004)
PROCTOR
SCRIPT
437
OS
5-year-OS
79·2% vs 80·4%
(HR 0·93)
5-year-DFS
55·4%vs62·7
%(HR0·80)
0.80 CI [0.60-
1.07]
(p=0·13).
GERCOR 357
69% preop
RT
DFS
OS HR =0.87 5-year DFS
58% vs 63%
0.80,
(p=0.154)
Chronicle
113
DFS
3-year-OS
89% vs 88%
(HR 1·18)
5-year DFS
71% vs 78%
0.80 (p=0.56)
ADORE 321
DFS
3-year-OS
86%vs95% (HR
0·46)
3-year DFS
63% vs 72%
0.63 (p=0.03)